Your browser doesn't support javascript.
loading
Ebola Virus Isolation Using Huh-7 Cells has Methodological Advantages and Similar Sensitivity to Isolation Using Other Cell Types and Suckling BALB/c Laboratory Mice.
Logue, James; Vargas Licona, Walter; Cooper, Timothy K; Reeder, Becky; Byrum, Russel; Qin, Jing; Deiuliis Murphy, Nicole; Cong, Yu; Bonilla, Amanda; Sword, Jennifer; Weaver, Wade; Kocher, Gregory; Olinger, Gene G; Jahrling, Peter B; Hensley, Lisa E; Bennett, Richard S.
Afiliação
  • Logue J; Integrated Research Facility, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 8200 Research Plaza, Frederick, MD 27102, USA. james.logue@nih.gov.
  • Vargas Licona W; Integrated Research Facility, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 8200 Research Plaza, Frederick, MD 27102, USA. wvargas@mriglobal.org.
  • Cooper TK; Integrated Research Facility, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 8200 Research Plaza, Frederick, MD 27102, USA. timothy.cooper@nih.gov.
  • Reeder B; Integrated Research Facility, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 8200 Research Plaza, Frederick, MD 27102, USA. rebecca.reeder@nih.gov.
  • Byrum R; Integrated Research Facility, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 8200 Research Plaza, Frederick, MD 27102, USA. byrumr@niaid.nih.gov.
  • Qin J; Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, 5601 Fishers Lane, Rockville, MD 20852, USA. jingqin@niaid.nih.gov.
  • Deiuliis Murphy N; Integrated Research Facility, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 8200 Research Plaza, Frederick, MD 27102, USA. nicole.deiuliis@nih.gov.
  • Cong Y; Integrated Research Facility, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 8200 Research Plaza, Frederick, MD 27102, USA. yu.cong@nih.gov.
  • Bonilla A; Integrated Research Facility, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 8200 Research Plaza, Frederick, MD 27102, USA. amanda.bonilla@nih.gov.
  • Sword J; Integrated Research Facility, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 8200 Research Plaza, Frederick, MD 27102, USA. jennifer.sword@nih.gov.
  • Weaver W; Integrated Research Facility, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 8200 Research Plaza, Frederick, MD 27102, USA. wade.weaver@nih.gov.
  • Kocher G; Integrated Research Facility, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 8200 Research Plaza, Frederick, MD 27102, USA. gregory.kocher@nih.gov.
  • Olinger GG; Integrated Research Facility, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 8200 Research Plaza, Frederick, MD 27102, USA. golinger@MRIGLOBAL.ORG.
  • Jahrling PB; Integrated Research Facility, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 8200 Research Plaza, Frederick, MD 27102, USA. jahrlingp@niaid.nih.gov.
  • Hensley LE; Emerging Viral Pathogens Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 8200 Research Plaza, Frederick, MD 21702, USA. jahrlingp@niaid.nih.gov.
  • Bennett RS; Integrated Research Facility, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 8200 Research Plaza, Frederick, MD 27102, USA. lisa.hensley@nih.gov.
Viruses ; 11(2)2019 02 16.
Article em En | MEDLINE | ID: mdl-30781518
Following the largest Ebola virus disease outbreak from 2013 to 2016, viral RNA has been detected in survivors from semen and breast milk long after disease recovery. However, as there have been few cases of sexual transmission, it is unclear whether every RNA positive fluid sample contains infectious virus. Virus isolation, typically using cell culture or animal models, can serve as a tool to determine the infectivity of patient samples. However, the sensitivity of these methods has not been assessed for the Ebola virus isolate, Makona. Described here is an efficiency comparison of Ebola virus Makona isolation using Vero E6, Huh-7, monocyte-derived macrophage cells, and suckling laboratory mice. Isolation sensitivity was similar in all methods tested. Laboratory mice and Huh-7 cells were less affected by toxicity from breast milk than Vero E6 and MDM cells. However, the advantages associated with isolation in Huh-7 cells over laboratory mice, including cost effectiveness, sample volume preservation, and a reduction in animal use, make Huh-7 cells the preferred substrate tested for Ebola virus Makona isolation.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Virologia / Ebolavirus Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Virologia / Ebolavirus Idioma: En Ano de publicação: 2019 Tipo de documento: Article